How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Transplantation of Hematopoietic Stem Cells Market
- By Transplant Type: Autologous Hematopoietic Stem Cell Transplantation, Allogeneic Hematopoietic Stem Cell Transplantation, Syngeneic Hematopoietic Stem Cell Transplantation
- By Stem Cell Source: Bone Marrow, Peripheral Blood Stem Cells (PBSC), Umbilical Cord Blood
- By Indication: Leukemia, Lymphoma, Multiple Myeloma, Aplastic Anemia, Inherited Blood Disorders
- By Conditioning Regimen: Myeloablative Conditioning, Reduced-Intensity Conditioning (RIC), Non-Myeloablative Conditioning
- By Donor Type: Matched Related Donor (MRD), Matched Unrelated Donor (MUD), Haploidentical Donor, Cord Blood Donor
Top segment
Autologous Hematopoietic Stem Cell Transplantation XX% share · $X,XXXM
In the full report →
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Autologous Hematopoietic Stem Cell Transplantation leads By Transplant Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 291 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.175 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.183 →
Full report · locked preview
Everything inside the Transplantation of Hematopoietic Stem Cells Market report
A complete, evidence-based study - 12 chapters and 122 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Transplant Type 3
Stem Cell Source 3
Indication 5
Conditioning Regimen 3
Donor Type 4
Companies profiled
Fresenius SE & Co. KGaA
Thermo Fisher Scientific Inc.
Miltenyi Biotec GmbH
Lonza Group AG
GE Healthcare Life Sciences (Cytiva)
Stemcell Technologies Inc.
Becton
Dickinson and Company (BD)
Macopharma
NantKwest Inc.
AllCells
CellGenix GmbH
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Fresenius SE & Co. KGaA
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Thermo Fisher Scientific Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Miltenyi Biotec GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Lonza Group AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →GE Healthcare Life Sciences (Cytiva)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Stemcell Technologies Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Becton
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Dickinson and Company (BD)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Macopharma
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →NantKwest Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →AllCells
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →CellGenix GmbH
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →BioLife Solutions Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Cryoport Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →CytomX Therapeutics Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Cytiva (formerly part of GE Healthcare)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$5,624M by 2033 · 6.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Autologous Hematopoietic Stem Cell Transplantation64.8
- Allogeneic Hematopoietic Stem Cell Transplantation15.9
- Syngeneic Hematopoietic Stem Cell Transplantation19.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,145M → $1,761M · 5.5%
Europe$798.2M → $1,184M · 5.0%
Asia Pacific$728.8M → $1,306M · 7.6%
Latin America$451.2M → $670.7M · 5.1%
Middle East and Africa$347.0M → $581.7M · 6.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →6.172026
6.182027
6.192028
6.212029
6.232030
6.242031
6.242032
6.262033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Fresenius SE & Co. KGaA14.8
- Thermo Fisher Scientific Inc.22.7
- Miltenyi Biotec GmbH4.2
- Lonza Group AG11.9
- GE Healthcare Life Sciences (Cytiva)7.6
- Stemcell Technologies Inc.10.8
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Transplant Type28.7%
Stem Cell Source23.8%
Indication22.8%
Conditioning Regimen16.1%
Donor Type8.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.0
- Europe21.5
- Asia Pacific23.7
- Latin America12.2
- Middle East and Africa10.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Fresenius SE & Co. KGaA | 93 | 95 | 93 | 85 | 97 | 74 | 90 |
| Thermo Fisher Scientific Inc. | 79 | 82 | 80 | 86 | 82 | 83 | 82 |
| Miltenyi Biotec GmbH | 64 | 64 | 67 | 69 | 79 | 86 | 72 |
| Lonza Group AG | 68 | 67 | 59 | 62 | 64 | 71 | 65 |
| GE Healthcare Life Sciences (Cytiva) | 63 | 68 | 71 | 75 | 74 | 66 | 70 |
| Stemcell Technologies Inc. | 67 | 70 | 58 | 70 | 68 | 71 | 67 |
| Becton | 53 | 55 | 57 | 51 | 51 | 61 | 55 |
| Dickinson and Company (BD) | 46 | 46 | 52 | 60 | 52 | 50 | 51 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Fresenius SE & Co. KGaA
- Thermo Fisher Scientific Inc.
- Miltenyi Biotec GmbH
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Fresenius SE & Co. KGaA | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Thermo Fisher Scientific Inc. | ✓ | ✓ | ✓ | ◐ | ✓ | ◐ |
| Miltenyi Biotec GmbH | − | ◐ | ◐ | ◐ | ✓ | ✓ |
| Lonza Group AG | ◐ | − | ◐ | ◐ | ◐ | ✓ |
| GE Healthcare Life Sciences (Cytiva) | ◐ | ✓ | ✓ | ✓ | ◐ | − |
| Stemcell Technologies Inc. | − | ◐ | ◐ | ✓ | ◐ | − |
| Becton | − | − | − | − | ◐ | ◐ |
| Dickinson and Company (BD) | ◐ | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Fresenius SE & Co. KGaA90
2Thermo Fisher Scientific Inc.82
3Miltenyi Biotec GmbH72
4GE Healthcare Life Sciences (Cytiva)70
5Stemcell Technologies Inc.67
6Lonza Group AG65
7Becton55
8Dickinson and Company (BD)51
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Fresenius SE & Co. KGaAThermo Fisher Scientific Inc.
Challenger3
Strong scale, closing on the leaders.
Miltenyi Biotec GmbHGE Healthcare Life Sciences (Cytiva)Stemcell Technologies Inc.
Contender1
Focused players with pockets of strength.
Lonza Group AG
Niche2
Specialists in a single segment or region.
BectonDickinson and Company (BD)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Transplant Type in North America, then scale across Transplantation of Hematopoietic Stem Cells Market — a $524M beachhead inside a $7.59B market.
Beachhead (SOM)$524Mobtainable near-term
Serviceable (SAM)$2.76Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Autologous Hematopoietic Stem Cell Transplantation
Best fit — highest urgency & budget in Transplant Type.
Economic buyer77 fit
Allogeneic Hematopoietic Stem Cell Transplantation
Strong fit — clear ROI and a fast path to value.
End user69 fit
Syngeneic Hematopoietic Stem Cell Transplantation
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Transplant Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Stem Cell Source & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel29%
Digital / self-serve21%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Transplant Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Transplantation of Hematopoietic Stem Cells Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified21%
Evaluation15%
Closed-won6%
$14.1KCAC
$53KLTV
3.8:1LTV : CAC
< 5 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Transplantation of Hematopoietic Stem Cells Market is a durable-growth opportunity — $7.65B by 2033, compounding at 8.4%.
TAM · 2025$4.00Btoday
TAM · 2033$7.65Bforecast
CAGR8.4%2027–2033
Cumulative$50.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$7.65BTotal addressable market
SAM$2.83BServiceable available market
SOM$502MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.4% CAGR
Demand compounds through 2033, outpacing GDP across Transplant Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Transplant Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$7.65BLarge & growingTAM by 2033 at 8.4% CAGR
$2.83BServiceable nowreachable with today’s model
$502MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$5.97BBear5.5% CAGR
$7.65BBase8.4% CAGR
$9.80BBull11.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Stem Cell Source optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Transplantation of Hematopoietic Stem Cells Market — a $1.76B market by 2033. Plan: grow share from 7.0% to 13.3%.
Market size · 2033$1.76Btotal addressable
Market CAGR5.9%2027–2033
Target share13.3%from 7.0% today
Revenue ambition$235Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.0% | 13.3% | On track |
| Revenue | $129M | $235M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 31.6% | 45.0% | Behind |
| Customer retention | 88.8% | 92.1% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Transplant Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Stem Cell Source capability
A defensible second engine — invest in Stem Cell Source to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Transplant Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Stem Cell Source
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $32M capacity & capability investment
- Greenlight bolt-on M&A in Stem Cell Source
- Authorise North America expansion plan
- Fund R&D program for Transplant Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Transplantation of Hematopoietic Stem Cells Market conversation — a $5.08B market you can size, segment and defend in minutes.
Market size · 2033$5.08Btotal opportunity
Growth4.9%CAGR to 2033
Addressable buyers1,749+accounts in scope
Typical ROI5.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Transplant Type
Goal Grow share in Transplant Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.8×return on cost, year one
< 3 mopayback period
$80K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Fresenius SE & Co. KGaAThermo Fisher Scientific Inc.Miltenyi Biotec GmbHLonza Group AGGE Healthcare Life Sciences (Cytiva)Stemcell Technologies Inc.BectonDickinson and Company (BD)+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Transplantation of Hematopoietic Stem Cells Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Transplantation of Hematopoietic Stem Cells Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Transperineal Access Biopsy Device Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportTransparent Wound Dressing Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportTransparent Wound Care Dressings Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportTransparent Thermostatic Water Bath Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportTransparent Self-adhesive Dressing Market
Market size, share, segmentation and regional forecast.
$308M market · 2025 base year
View reportTransparent Film Wound Dressing Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportTransparent Film Dressings Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportTransparent Dental Materials Market
Market size, share, segmentation and regional forecast.
$402M market · 2025 base year
View reportTransparent Dental Braces Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportTransparent Correction Braces Market
Market size, share, segmentation and regional forecast.
$3.1B market · 2025 base year
View reportTransparent Ceramic Braces Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportTransparent Braces Market
Market size, share, segmentation and regional forecast.
$1.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.